Related Experiment Videos
Androgen therapy in chronic renal failure
1Royal Prince Alfred Hospital, Department of Medicine, University of Sydney, NSW, Australia.
Bailliere'S Clinical Endocrinology and Metabolism
|May 20, 1999
Summary
Chronic renal failure significantly impacts male reproductive health, affecting sperm production and sexual function. This review explores gonadotropin and androgen therapies for uraemic hypogonadism, suggesting potential benefits for male infertility.
Area of Science:
- Nephrology
- Andrology
- Endocrinology
Background:
- Chronic renal failure (CRF) severely impacts male reproductive health, leading to impaired spermatogenesis, steroidogenesis, and sexual function.
- Uremia-induced hypothalamo-pituitary testicular dysfunction manifests as delayed growth, sexual dysfunction, androgen deficiency, and infertility.
Purpose of the Study:
- To review the clinical applications of gonadotropin and androgen therapy in chronic renal failure patients.
- To explore the potential of these therapies as adjuncts to standard medical care for CRF.
Main Methods:
- Review of existing experimental and clinical findings.
- Analysis of therapeutic possibilities for uraemic hypogonadism.
Main Results:
- CRF significantly impairs male fertility and sexual health.
- Androgen therapy lacks proven indications in CRF, except for renal anemia.
- Uraemic hypogonadism may represent a functional gonadotropin deficiency.
Conclusions:
- Gonadotropin and androgen therapies offer potential as adjunct treatments for male reproductive health issues in CRF.
- Further research is warranted to elucidate the role of gonadotropin therapy in managing uraemic hypogonadism and infertility.